Studies reveal how kinin receptor antagonists achieve subtype selectivity and identify BDNF as a direct TLR4 antagonist, highlighting BDP-12 as a potential therapy for acute inflammatory diseases.
Enveric Biosciences reports positive preclinical results for lead candidate EB-003 showing efficacy in depression and PTSD models. The company has completed pre-IND studies and received FDA feedback for streamlined IND submission, with plans for Phase 1 trials in 2026. New BRET assay data demonstrates EB-003's engagement of therapeutic signaling pathways while independent research supports separation from hallucinogenic effects.
Systematic review identifies shared molecular signatures in brain and blood for major depressive disorder, while separate study finds brain-enriched circRNA can predict SSRI treatment response.
